Interim Analysis of the 2nd Chance Protocol: A Multicenter Trial of Daratumumab, Carfilzomib, Lenalidomide, & Dexamethasone for Relapsed/Refractory Myeloma with Salvage Autologous Hematopoietic Cell Transplantation

Autor:	Gunjan L. Shah, Susan Bal, Cesar Rodriguez, Saurabh Chhabra, Ruthee-Lu Bayer, Luciano J. Costa, Jonathan Lambird, Christine Ferrer, Allison Parascondola, Leeann Marcello, Leah Shulman, Obadi Obadi, Jennifer Acosta, Hani Hassoun, Malin Hultcrantz, Neha S. Korde, Sham Mailankody, Carlyn Rose Tan, Urvi A. Shah, Alexander M. Lesokhin, Oscar B. Lahoud, Michael Scordo, David J. Chung, Heather J Landau, Sergio A Giralt
Rok vydání:	2022
Předmět:	Transplantation Molecular Medicine Immunology and Allergy Cell Biology Hematology
Zdroj:	Transplantation and Cellular Therapy. 28:S415-S416
ISSN:	2666-6367
DOI:	10.1016/s2666-6367(22)00693-5
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0e05aefef81da978b7fcfc659182f416 https://doi.org/10.1016/s2666-6367(22)00693-5 Zobrazit plný text záznamu Full Text from ScienceDirect